Northern Trust’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-805,236
| Closed | -$42.5M | – | 4560 |
|
|
2026
Q1 | $42.5M | Buy |
805,236
+140,792
| +21% | +$5.78M | 0.01% | 1210 |
|
|
2025
Q4 | $26.8M | Buy |
664,444
+76,899
| +13% | +$1.78M | ﹤0.01% | 1483 |
|
|
2025
Q3 | $4.41M | Buy |
587,545
+16,764
| +3% | +$107K | ﹤0.01% | 2570 |
|
|
2025
Q2 | $2.13M | Sell |
570,781
-13,407
| -2% | -$41.9K | ﹤0.01% | 2943 |
|
|
2025
Q1 | $1.61M | Sell |
584,188
-6,983
| -1% | -$28.5K | ﹤0.01% | 3034 |
|
|
2024
Q4 | $3.28M | Buy |
591,171
+127,296
| +27% | +$862K | ﹤0.01% | 2760 |
|
|
2024
Q3 | $3.87M | Buy |
463,875
+116,108
| +33% | +$955K | ﹤0.01% | 2627 |
|
|
2024
Q2 | $2.37M | Sell |
347,767
-8,029
| -2% | -$48.6K | ﹤0.01% | 2810 |
|
|
2024
Q1 | $2.33M | Sell |
355,796
-2,708
| -0.8% | -$17.7K | ﹤0.01% | 2879 |
|
|
2023
Q4 | $2.33M | Buy |
358,504
+10,184
| +3% | +$53.8K | ﹤0.01% | 2907 |
|
|
2023
Q3 | $1.75M | Sell |
348,320
-13,295
| -4% | -$84.4K | ﹤0.01% | 3014 |
|
|
2023
Q2 | $3.16M | Buy |
361,615
+306,536
| +557% | +$3.57M | ﹤0.01% | 2755 |
|
|
2023
Q1 | $652K | Buy |
55,079
+23,486
| +74% | +$224K | ﹤0.01% | 3354 |
|
|
2022
Q4 | $322K | Buy |
31,593
+10,089
| +47% | +$67.2K | ﹤0.01% | 3653 |
|
|
2022
Q3 | $127K | Buy |
21,504
+7,131
| +50% | +$26.5K | ﹤0.01% | 4033 |
|
|
2022
Q2 | $36K | Sell |
14,373
-90,449
| -86% | -$181K | ﹤0.01% | 4502 |
|
|
2022
Q1 | $311K | Sell |
104,822
-7,214
| -6% | -$30.8K | ﹤0.01% | 3933 |
|
|
2021
Q4 | $792K | Sell |
112,036
-4,880
| -4% | -$40.6K | ﹤0.01% | 3630 |
|
|
2021
Q3 | $1.22M | Buy |
116,916
+30,133
| +35% | +$313K | ﹤0.01% | 3489 |
|
|
2021
Q2 | $1.06M | Sell |
86,783
-5,004
| -5% | -$85.2K | ﹤0.01% | 3513 |
|
|
2021
Q1 | $2.02M | Buy |
+91,787
| New | +$2.01M | ﹤0.01% | 3236 |
|
Other funds holding TERN
Northern Trust's TERN Position: Q2 2026 in Review
Northern Trust sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 805,236 shares — an estimated $42.5M sold.
Northern Trust first reported a position in TERN in Q1 2021 and held it in 21 quarters. The position peaked at $42.5M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Northern Trust reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Northern Trust sold 805,236 Terns Pharmaceuticals shares in Q2 2026, an estimated $42.5M.
- Northern Trust first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 21 quarters.
- Northern Trust's Terns Pharmaceuticals position peaked at $42.5M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.